Entera Bio Q3 net loss widens to $15.6 million from $3.2 million
Entera Bio reported a third-quarter 2026 net loss of $15.6 million, or $0.11 per share, up from $3.2 million, or $0.07 per share, a year earlier. The company reported no revenue in either period, and the filing attributes the increase mainly to a $7.5 million non-cash fair value remeasurement of pre-funded warrants. Shareholders also got an update that the first clinical site for the EB613 Phase 3 osteoporosis study is expected to be activated in late 2026, with cash of $265.9 million as of September 30, 2026.
Key points
- Net loss was $15.6 million for the three months ended September 30, 2026, compared with $3.2 million a year earlier.
- The loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants.
- Research and development expenses rose to $4.9 million from $1.6 million, mainly for EB613 Phase 3 start-up and the OPKO collaboration.
- Cash and cash equivalents were $265.9 million as of September 30, 2026, following a July 2026 private placement with gross proceeds of approximately $275.0 million.
The filing
Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.